249 related articles for article (PubMed ID: 8608123)
41. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor.
Hessler JL; Kreitman RJ
Biochemistry; 1997 Nov; 36(47):14577-82. PubMed ID: 9398176
[TBL] [Abstract][Full Text] [Related]
42. Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL.
Pitcher C; Roberts L; Fawell S; Zdanovsky AG; FitzGerald DJ; Lord JM
Bioconjug Chem; 1995; 6(5):624-9. PubMed ID: 8974463
[TBL] [Abstract][Full Text] [Related]
43. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
44. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
Debinski W; Pastan I
Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
[TBL] [Abstract][Full Text] [Related]
45. Expression and purification of recombinant immunotoxin--a fusion protein stabilizes a single-chain Fv (scFv) in denaturing condition.
Kim SH
Protein Expr Purif; 2003 Jan; 27(1):85-9. PubMed ID: 12509988
[TBL] [Abstract][Full Text] [Related]
46. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.
Ogata M; Fryling CM; Pastan I; FitzGerald DJ
J Biol Chem; 1992 Dec; 267(35):25396-401. PubMed ID: 1460035
[TBL] [Abstract][Full Text] [Related]
47. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.
Buchner J; Pastan I; Brinkmann U
Anal Biochem; 1992 Sep; 205(2):263-70. PubMed ID: 1332541
[TBL] [Abstract][Full Text] [Related]
48. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
[TBL] [Abstract][Full Text] [Related]
49. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
50. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
[TBL] [Abstract][Full Text] [Related]
51. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; Waldman TA; Pastan I
Blood; 1992 Nov; 80(9):2344-52. PubMed ID: 1421405
[TBL] [Abstract][Full Text] [Related]
52. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
[TBL] [Abstract][Full Text] [Related]
53. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann T; Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8291-5. PubMed ID: 2236041
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
55. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity.
Kreitman RJ; Puri RK; Leland P; Lee B; Pastan I
Biochemistry; 1994 Sep; 33(38):11637-44. PubMed ID: 7918378
[TBL] [Abstract][Full Text] [Related]
56. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
57. Purification of clinical-grade disulfide stabilized antibody fragment variable--Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli.
Jiang H; Xie Y; Burnette A; Roach J; Giardina SL; Hecht TT; Creekmore SP; Mitra G; Zhu J
Appl Microbiol Biotechnol; 2013 Jan; 97(2):621-32. PubMed ID: 22890777
[TBL] [Abstract][Full Text] [Related]
58. A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing.
Theuer CP; FitzGerald D; Pastan I
J Biol Chem; 1992 Aug; 267(24):16872-7. PubMed ID: 1512230
[TBL] [Abstract][Full Text] [Related]
59. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
Chaudry GJ; Fulton RJ; Draper RK
J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
[TBL] [Abstract][Full Text] [Related]
60. Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.
McHugh L; Hu S; Lee BK; Santora K; Kennedy PE; Berger EA; Pastan I; Hamer DH
J Biol Chem; 2002 Sep; 277(37):34383-90. PubMed ID: 12119300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
